In this multi-year, multi-target collaboration, Ochre Bio’s proprietary discovery platform combines RNA synthesis, deep phenotyping, and human-organ perfusion models to accelerate the discovery of novel targets for undertreated liver diseases
BI aims to develop a treatment that is capable of increasing the liver’s self-repair capability which could eventually reduce disease progression by modifying regenerative targets
Moreover, Ochre Bio will receive upfront and research-based milestone payments of $35M. It will be eligible to receive additional payments incl. (regulatory, commercial, and clinical success plus tiered royalties), and an overall deal value is expected to exceed $1B
Ref: Ochre Bio | Image: Ochre Bio
Related News:- Eli Lilly and Boehringer Ingelheim Report the P-III (EMPACT-MI) Study Data of Jardiance on Risk of Heart Failure and Death Following a Heart Attack
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
